{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:09:33Z","timestamp":1760058573182,"version":"build-2065373602"},"reference-count":26,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Youth-onset type 2 diabetes (YO-T2D) is on the rise and disproportionately affects those from low socioeconomic status and specific ethnic and racial minority groups. YO-T2D has a more aggressive phenotype than adult-onset T2D. We present a case of a 14-year-old patient who presented after a fall and was found to be acutely unwell with significant peripheral edema. Initial investigations indicated hyperglycemic hyperosmolar state, acute kidney injury, and nephrotic range proteinuria, leading to a new diagnosis of T2D. Subsequent evaluation revealed mild retinopathy and diabetic nephropathy. Sixteen months prior, glycated hemoglobin (HbA1c) was &amp;gt;\u202f16% (reference range, \u2264\u202f6.0%) with no treatment initiated at that time. The patient was initially treated with multiple daily insulin injections prior to starting empagliflozin-metformin. The presence of developmental delays, short stature, and hypogonadism prompted genetic testing, which confirmed a diagnosis of Prader-Willi syndrome, a neurodevelopmental disorder associated with hyperphagia and early-onset obesity. This case underscored the severity of YO-T2D, risks of delayed healthcare access, and considerations for optimal diabetes management.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf221","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:36:54Z","timestamp":1758796614000},"source":"Crossref","is-referenced-by-count":0,"title":["Late Diagnosis of Prader-Willi Syndrome in an Adolescent With Significant Complications of Type 2 Diabetes"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-5115","authenticated-orcid":false,"given":"Alyssa","family":"Kahane","sequence":"first","affiliation":[{"name":"Department of Paediatrics, The Hospital for Sick Children , Toronto, ON M5G 1X8 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Metivier","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto , Toronto, ON M5G 1X8 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Bahm","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Peel Memorial Hospital , Brampton, ON L6W 2Z8 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-2800","authenticated-orcid":false,"given":"Jill","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto , Toronto, ON M5G 1X8 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2025100913161832200_luaf221-B1","doi-asserted-by":"crossref","first-page":"5511049","DOI":"10.1155\/2023\/5511049","article-title":"Incidence trends of type 2 diabetes mellitus, medication-induced diabetes, and monogenic diabetes in Canadian children, then (2006\u20132008) and now (2017\u20132019)","volume":"2023","author":"Patel","year":"2023","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"2025100913161832200_luaf221-B2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11892-024-01546-2","article-title":"Youth-onset type 2 diabetes: an overview of pathophysiology, prognosis, prevention and management","volume":"24","author":"Titmuss","year":"2024","journal-title":"Curr Diab Rep"},{"issue":"3","key":"2025100913161832200_luaf221-B3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ajem.2005.10.007","article-title":"Pediatric hyperglycemic hyperosmolar syndrome: diagnostic difficulties and high mortality rate","volume":"24","author":"Cochran","year":"2006","journal-title":"Am J Emerg Med"},{"issue":"8","key":"2025100913161832200_luaf221-B4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4239\/wjd.v13.i8.587","article-title":"Diabetic kidney disease in pediatric patients: a current review","volume":"13","author":"Muntean","year":"2022","journal-title":"World J Diabetes"},{"issue":"4","key":"2025100913161832200_luaf221-B5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1573396315666190716120925","article-title":"Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update","volume":"15","author":"Butler","year":"2019","journal-title":"Curr Pediatr Rev"},{"issue":"4","key":"2025100913161832200_luaf221-B6","first-page":"248","article-title":"Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study","volume":"44","author":"Butler","year":"2002","journal-title":"Dev Med Child Neurol"},{"issue":"22","key":"2025100913161832200_luaf221-B7","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.3390\/jcm10225310","article-title":"Diabetes Mellitus in Prader-Willi Syndrome: natural history during the transition from childhood to adulthood in a cohort of 39 patients","volume":"10","author":"Clerc","year":"2021","journal-title":"J Clin Med"},{"issue":"Supplement_1","key":"2025100913161832200_luaf221-B8","doi-asserted-by":"crossref","first-page":"A601","DOI":"10.1210\/jendso\/bvac150.1248","article-title":"ODP383 clinical presentation and management of diabetes Mellitus in youth with Prader-Willi Syndrome","volume":"6","author":"Paprocki","year":"2022","journal-title":"J Endocr Soc"},{"author":"Adeyinka","key":"2025100913161832200_luaf221-B9"},{"key":"2025100913161832200_luaf221-B10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pedi.12281","article-title":"Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium","volume":"17","author":"Klingensmith","year":"2016","journal-title":"Pediatr Diabetes"},{"key":"2025100913161832200_luaf221-B11","doi-asserted-by":"crossref","first-page":"1318136","DOI":"10.1155\/2023\/1318136","article-title":"Risk factors for hyperosmolar hyperglycemic state in pediatric type 2 diabetes","volume":"2023","author":"Everett","year":"2023","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"2025100913161832200_luaf221-B12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/pch\/pxad073","article-title":"Hyperglycemic hyperosmolar state: no longer an endocrine crisis exclusive to adulthood","volume":"29","author":"Ryan","year":"2024","journal-title":"Paediatrics Child Health"},{"issue":"3","key":"2025100913161832200_luaf221-B13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1399-543X.2005.00113.x","article-title":"Hyperglycemic hyperosmolar non-ketotic syndrome in children with type 2 diabetes","volume":"6","author":"Fourtner","year":"2005","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"2025100913161832200_luaf221-B14","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.2337\/dc20-1258","article-title":"An update on the incidence and burden of diabetic ketoacidosis in the U.S","volume":"43","author":"Ramphul","year":"2020","journal-title":"Diabetes Care"},{"issue":"3","key":"2025100913161832200_luaf221-B15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1515\/JPEM.2004.17.3.361","article-title":"Diabetic ketoacidosis secondary to growth hormone treatment in a boy with Prader-Willi syndrome and steatohepatitis","volume":"17","author":"Yigit","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2025100913161832200_luaf221-B16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa2100165","article-title":"Long-term complications in youth-onset type 2 diabetes","volume":"385","author":"TODAY Study Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100913161832200_luaf221-B17","first-page":"102240","article-title":"Nephrotic-range proteinuria in type 2 diabetes: effects of empagliflozin on kidney disease progression and clinical outcomes","volume":"43","author":"Ruggenenti","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2025100913161832200_luaf221-B18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11892-020-1284-5","article-title":"Update on diabetes mellitus and glucose metabolism alterations in Prader-Willi syndrome","volume":"20","author":"Crin\u00f2","year":"2020","journal-title":"Curr Diab Rep"},{"issue":"1","key":"2025100913161832200_luaf221-B19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13023-017-0702-5","article-title":"Prevalence and risk factors for type 2 diabetes mellitus with Prader-Willi syndrome: a single center experience","volume":"12","author":"Yang","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2025100913161832200_luaf221-B20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.21037\/tp-23-518","article-title":"Early onset stage III diabetic nephropathy in a child with Prader-Willi syndrome treated with dulaglutide: a case report","volume":"13","author":"He","year":"2024","journal-title":"Transl Pediatr"},{"issue":"8","key":"2025100913161832200_luaf221-B21","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/pedi.13444","article-title":"ISPAD clinical practice consensus guidelines 2022: microvascular and macrovascular complications in children and adolescents with diabetes","volume":"23","author":"Bjornstad","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"2025100913161832200_luaf221-B22","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"2025100913161832200_luaf221-B23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","article-title":"Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial","volume":"11","author":"Laffel","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2025100913161832200_luaf221-B24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","article-title":"Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study","volume":"10","author":"Tamborlane","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2025100913161832200_luaf221-B25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/pedi.13409","article-title":"ISPAD clinical practice consensus guidelines 2022: type 2 diabetes mellitus in youth","volume":"23","author":"Shah","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2025100913161832200_luaf221-B26"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/11\/luaf221\/64380113\/luaf221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/11\/luaf221\/64380113\/luaf221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:16:31Z","timestamp":1760030191000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf221\/8263536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf221","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,25]]},"article-number":"luaf221"}}